Dr. Reddy's Reports 11% YoY Revenue Growth for Q1 FY26; Profit Up 2%
The announcement of quarterly financial results is a significant event for investors. The mixed financial performance, with YoY growth offset by QoQ declines in key profitability metrics and anticipated pricing pressure in a major market, suggests a medium impact as investors will weigh both positive and negative aspects.
While the company reported double-digit YoY revenue growth and a rise in profit, there was a QoQ decline in profit and EBITDA. The significant decline in North America revenue due to intensifying pricing pressure on a key product (Lenalidomide) also contributes to a neutral outlook.
* Dr. Reddy's Laboratories Limited announced its consolidated financial results for the quarter ended 30 June 25. * Revenues for Q1 FY26 stood at ₹8,545.2 crore, marking an 11% year-on-year (YoY) increase, while remaining flat quarter-on-quarter (QoQ). * Profit after Tax (PAT) attributable to equity holders was ₹1,417.8 crore, up 2% YoY, but down 11% QoQ. * Earnings Before Interest, Tax, Depreciation & Amortization (EBITDA) was ₹2,278.4 crore (26.7% of revenues), growing 5% YoY but declining 8% QoQ. * Diluted Earnings Per Share (EPS) for the quarter was ₹17.02. * Segment-wise revenue highlights: * Global Generics revenue was ₹7,562 crore, a 10% YoY increase. * North America revenues declined by 11% YoY to ₹3,412.3 crore, primarily due to increased price erosion in certain key products, including Lenalidomide. * Europe revenues surged 142% YoY to ₹1,274.4 crore, driven by the acquired Nicotine Replacement Therapy (NRT) business. * India revenues grew 11% YoY to ₹1,471.1 crore, fueled by new product introductions and price increases. * Emerging Markets revenues increased 18% YoY to ₹1,404.2 crore, with Russia contributing ₹710 crore (up 28% YoY). * Pharmaceutical Services and Active Ingredients (PSAI) revenues grew 7% YoY to ₹818.1 crore. * Co-Chairman & MD, G V Prasad commented: "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development." * Key business highlights include expanded partnerships with Alvotech for a pembrolizumab biosimilar and with Sanofi to launch Beyfortus™ in India. * The company reported a Capital Expenditure of ₹680 crore and a Free Cash Flow of ₹450 crore for the quarter. * Net Cash Surplus stood at ₹2,920 crore as on 30 June 25, with Net Debt to Equity at (0.08). * The company improved its rating by Carbon Disclosure Project (CDP) to 'A' in the Climate category.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.